Akebia Therapeutics Inc（AKBA）財務資料AKBAAkebia Therapeutics Inc

Evaluating the bottom line, Akebia Therapeutics Inc maintains a gross margin of 80.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.46%, while the net margin is -18.13%. These profitability ratios, combined with a Return on Equity (ROE) of -109.38%, provide a clear picture of how effectively AKBA converts its operational activities into shareholder value.

In the context of the broader market, AKBA competes directly with industry leaders such as PRQR and EVMN. With a market capitalization of $171.28M, it holds a significant position in the sector. When comparing efficiency, AKBA's gross margin of 80.50% stands against PRQR's 100.00% and EVMN's N/A. Such benchmarking helps identify whether Akebia Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Akebia's financial performance is concerning, with a gross margin of 80.50% in Q2 2026 but a net income loss of $8.9 million. The company has seen a significant decline in revenue, with Q2 2026 revenue at $49 million, down from previous quarters.